Non-insulin-dependent type

Treatment of insulin-dependent type 1 diabetes mellitus and non-insulin-dependent type 2 diabetes mellitus when diet or weight control has failed to maintain satisfactory blood glucose levels or in event of fever, infection, surgery, ortrauma, or severe endocrine, hepatic, or renal dysfunction emergency treatment of ketoacidosis (regular insulin) to... 

It is a very potent sulfonylurea with long duration of action indicated in non-insulin dependent (type II) diabetes, whenever blood sugar levels can not be controlled adequately by diet, physical exercise or reduction in body weight. 

South Asian populations. People of South Asian origin in the UK have a high prevalence of coronary heart disease and stroke, central obesity (as evidenced by high waist-to-hip ratio), insulin resistance, non-insulin-dependent (type 2) diabetes and hypertension (Cappuccio 1997 Kain et al. 2002 Bhopal et al. 2005). This increase in vascular risk seems to be partly a result of genetic susceptibility, such as high serum lipoprotein A levels, and partly dietary- and lifestyle-induced changes in lipid levels. 

It can be seen from Table 2 that a large number of the naturally-occurring polyhydroxylated alkaloids are potent inhibitors of the various a-glucosidase-specific disaccharidases involved in mammalian digestion (e.g. sucrase, maltase, isomaltase, etc.,). These enzymes are expressed at the surface of the epithelial cells of the brush border in the small intestine. In the late 1970s it was realised that inhibitors of these enzymes, such as DNJ, could be used therapeutically in the oral treatment of the non-insulin-dependent (type n) diabetes mellitus. ... 

There is less consensus with regard to non-insulin-dependent (Type-II) diabetic patients about when to use what medication, and particularly at what point insulin therapy is appropriate. The natural history in obese Type-II diabetes patients usually starts with both impaired B-cell function and insulin resistance and/or basal hyperinsulinaemia resulting in elevated fasting blood glucose levels. 

Lebovitz HE, Clark CM, DeFronzo RA, et al., for the American Diabetes Association Clinical Education Program. Physician s guide to non-insulin-dependent (type II) diabetes. Diagnosis and treatment, 2nd edition. American Diabetes Association, 1990. 

Insulin-dependent diabetes is an absolute contraindication to a phenol peel. Diabetes significantly increases the risk of secondary infection the vascular and/or immune disorders associated with this illness mean that complications are more of a probability than a possibility. Stabilized, non-insulin-dependent type 2 diabetes is not an absolute contraindication to a phenol peel. The doctor must take particular care with these patients to avoid secondary infections. 

Diabetes mellitus, a chronic metabolic disease cause by insulin deficiency. This disease results from either insuSident insulin secretion or decreased sensitivity of the insulin receptor in the target cells. Two types of diabetes mellitus are known, insulin-dependent (type I) diabetes mellitus (IDDM), also termed juvenile-onset diabetes mellitus, caused by a deficiency of pancreatic fi cells and often strikes suddenly in childhood, and non-insulin-dependent (type II) diabetes mellitus (NIDDM), that may be associated with loss of fuUy active insulin receptors on normally insulin-responsive cells and is strongly cor-rdated with obesity. Although more than 80 years have passed since the discovery of insulin, the molecular actions of insulin have only begun to be investigated... 

NIDDM, non-insulin-dependent (type II) diabetes mellitus. 

Nagi DK, Ali VM, Yudkin JS. Effect of metformin on intact proinsulin and des 31,32 proinsulin concentrations in subjects with non-insulin-dependent (type 2) diabetes mellitus. Diabet Med 1996 13 753-757. 

Uusitupa H Sedervik H, Silvasti M, Karttunen P. Effects of a gel forming diet fiber, guar gum, on die absorption of glibenclamide and metabolic control and serum lipids in patients with non-insulin-dependent (type 2) diabetes. IntJ Clin Pharmacol Ther Toxicol (1990) 28, 153-7. 

Blevins, S.M., Leyva, M.J., Brown, J., Wright, J., Scofield, R.H., and Aston, C.E. 2007. Effect of cinnamon on glucose and lipid levels in non insulin-dependent type 2 diabetes. Diabetes care, 30 2236-2237. 

Monoester 4-(methoxycarbonyl)bicyclo[2.2.1]heptane-l-carboxylic acid 59 (Figure 4.17) is a building block of many potential therapeutic candidates for inhibitors of 11-p-hydroxysteroid dehydrogenase type 1 enzyme and their use in the treatment of non-insulin-dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, and CNS disorders. It is also required for the synthesis of 5-hydroxytryptamine receptor agonists, useful for the treatment of anxiety disorders and schizophrenia [90,91]. 

---